Reducing the Risk of PIRA in RRMS: The Value of High-efficacy Disease-Modifying Therapies (P4-20.005)

Maria Flor Guarnaschelli; Mariano Marrodan; Braian Sosa; Carolina Perez Arana; M Farez; Marcela Fiol; Ysrraelit Celica; Jorge Correale

doi:10.1212/wnl.0000000000215966

June 9, 2026Neurology

Reducing the Risk of PIRA in RRMS: The Value of High-efficacy Disease-Modifying Therapies (P4-20.005)

View at Publisher

Ask AI

Bookmark

Share

Key result

High-efficacy DMTs reduce progression independent of relapse activity in relapsing-remitting MS.

Key Points

Assess the association between disease-modifying therapy efficacy levels and the risk of developing progression independent of relapse activity in individuals with relapsing-remitting multiple sclerosis.
Evaluated patients diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Analyzed the occurrence of progression independent of relapse activity (PIRA) stratified by disease-modifying therapy (DMT) efficacy tiers.
High-efficacy disease-modifying therapies are associated with a reduced incidence of progression independent of relapse activity compared to lower-efficacy options.
Treatment selection significantly influences long-term disability accumulation occurring outside the context of acute relapses.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinical investigation demonstrates reduced risk of progression independent of relapse activity in relapsing-remitting multiple sclerosis, highlighting the protective benefit of high-efficacy...

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Guarnaschelli et al. (2026) studied this question. High-efficacy disease-modifying therapies reduce the risk of progression independent of relapse activity (PIRA) in patients with relapsing-remitting multiple sclerosis.

synapsesocial.com/papers/6a2bb2958101cf8926f038ae https://doi.org/10.1212/wnl.0000000000215966

View at Publisher

Ask AI

Bookmark

Share

Reducing the Risk of PIRA in RRMS: The Value of High-efficacy Disease-Modifying Therapies (P4-20.005)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Reducing the Risk of PIRA in RRMS: The Value of High-efficacy Disease-Modifying Therapies (P4-20.005)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading